Kite and Gadeta B.V. have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.  Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones.  In addition, Kite will make an upfront purchase of equity in Gadeta from Gadeta’s shareholders and may acquire additional equity in Gadeta upon ach...